AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04382664 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is dosed according to label.
Study NCT06119750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: This will be administered via skin patch.
Study NCT06119750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLS
Description: This will be administered via skin patch.
Study NCT04382664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is dosed according to label.
Study NCT01860183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
Study NCT01860183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
Study NCT05853328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epley Maneuver
Description: The patient is sitting with both feet on the table or bed with the head looking forward. Subsequently, they let themselves fall backwards with a pillow under the shoulder and the head is turned 45° to the right. They stay in this position for 30 seconds. Afterwards, they turn the head quickly 90° to the left side followed by a turn of the whole body to the left so that their nose is pointing at the floor. They stay in this position for another 30 seconds.~Subsequently, the patients sit themselves up with the head still turned 45° to the left. They can help themselves by using both arms. After a few seconds, they can turn the head slowly back to the neutral position facing forward.
Study NCT05853328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SemontPLUS maneuver
Description: The patients first turn head 45° to the left. Then they extend the right arm and subsequently move the whole body by 150°+ to the right side. This position is kept for 60 seconds. Subsequently, patients move their whole body by 240° towards the non-affected side. Finally, after another 60 seconds, the patient sits up for another 60 sec.
Study NCT02794220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CN electronic cigarette 10 mg
Description: Inhalation
Study NCT02794220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CN electronic cigarette 15 mg
Description: Inhalation
Study NCT02794220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Inhalator 15 mg
Description: Inhalation
Study NCT02794220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Inhalation
Study NCT02463955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible video endoscope
Description: Thoracoscopy is done using flexible video endoscope
Study NCT02463955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-rigid thoracoscope
Description: Thoracoscopy is done using video-rigid thoracoscope
Study NCT00855660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg
Description: Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
Study NCT00855660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a single tablet, thrice daily, over 14 days.
Study NCT02641535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise under hot and humid conditions protocol
Description: acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously.
Study NCT02641535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BC membrane protective garment
Study NCT02641535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBC mask
Study NCT02790866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LuCaS Decision Aid
Description: Web-based Lung Cancer Screening Decision Aid
Study NCT00966914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
Description: Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
Study NCT02601313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
Study NCT02601313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT02601313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT02790866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Website
Description: NCI Website on Lung Cancer Screening
Study NCT02601313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
Study NCT00966914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with cisplatin and docetaxel or paclitaxel
Description: Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
Study NCT04347603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Femoral percutaneous aortic prosthesis (TAVR)
Study NCT04347603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR
Description: Femoral percutaneous aortic prosthesis (TAVR)
Study NCT01796951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily
Description: In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
Study NCT01796951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Description: In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
Study NCT02675556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells
Study NCT02675556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
Study NCT02678494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Study NCT03057366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study NCT03057366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Pevonedistat
Description: \[14C\]-Pevonedistat intravenous infusion.
Study NCT03057366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion.
Study NCT03057366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion.
Study NCT03057366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion.
Study NCT03562663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
Study NCT03562663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper extremity robotics
Description: Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
Study NCT03562663 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Upper extremity robotics
Description: Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
Study NCT01931761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C14] selumetinib (oral)
Description: Single oral administration \[C14\] 75mg
Study NCT03324204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
Study NCT03324204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
Study NCT01294384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose sodium based New Eye Drop Formulation 1
Description: 1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
Study NCT01294384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose sodium based New Eye Drop Formulation 2
Description: 1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
Study NCT01294384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium based Eye Drops
Description: 1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
Study NCT01324284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
Study NCT00652353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 44-55-66-PM
Description: The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar
Study NCT00652353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
Study NCT02012556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Study NCT02117726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine,midazolam
Study NCT02117726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol,midazolam
Study NCT02803164 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wound Vacuum-assisted dressing
Description: The NPWT system (V.A.C. Therapy System, KCI USA Inc.) consisted of a medical-grade non-adherent polyvinyl alcohol white foam applied directly to the infected surface, followed by an open-pore reticulated polyurethane black foam cut to fit the wound and covered by a transparent air-tight adhesive drape. A suction cup with tubing was placed over a small slit on the drape and connected to a suction machine (V.A.C. ULTA Therapy Unit).
Study NCT02803164 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
Study NCT02070107 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: On Plan
Description: On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance.
Study NCT04167345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-814
Description: Tablet for oral administration.
Study NCT04167345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-814 for oral administration.
Study NCT04357106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma obtained by aphaeresis from recovered patients.
Study NCT00859365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real Acupuncture
Description: Real acupuncture treatment in real acupuncture points
Study NCT00859365 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
Study NCT00859365 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: No intervention
Description: Patients lay down for a period of 35 minutes without any treatment o intervention
Study NCT04227756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo
Study NCT04227756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 20 mg per os, single dose
Study NCT04227756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mescaline
Description: Mescaline 300 mg or 500 mg per os, single dose
Study NCT04227756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Mannitol)
Study NCT00699348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Description: Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
Study NCT04523974 — intervention group
Intervention type: PROCEDURE
Intervention: Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT
Description: 1. Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~2. Rapid immunoreactive parathyroid hormone detection technology during peri-operative period.
Study NCT00618748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5-20 mg/day, oral, daily
Study NCT01004757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LOGI diet
Description: diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
Study NCT01004757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat diet
Description: traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
Study NCT01944085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Syrup
Study NCT01944085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Syrup
Study NCT01944085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Syrup
Study NCT01144585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning and postconditioning
Description: RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB.
Study NCT01144585 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
Study NCT00445887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00445887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00445887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Given orally
Study NCT00445887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levonorgestrel
Description: Given orally
Study NCT00445887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT02070861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventricular pacing and passive leg raise
Description: Ventricular pacing and passive leg raise
Study NCT01707030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Brief Alcohol Intervention
Description: Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
Study NCT01707030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
Study NCT01707030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
Study NCT05220592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based recovery training program
Description: The iRTP was based on recovery experiences (psychological detachment, relaxation, mastery, and control), converted into a recovery training intervention, and inspired by Hahn et al. (2011). The iRTP comprised five modules distributed over five weeks, with modules lasting 60-120 minutes per week. Each module contained psycho education, worksheets, images, cases, audio and video files, and homework assignments.
Study NCT01449708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA NoNarc
Description: * patients in both groups receive antiemetic prophylaxis~* patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~* postop management in both groups is similar in both groups
Study NCT03723681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib is provided as 20 mg tablets for oral administration
Study NCT05434832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Distraction method
Study NCT05434832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local cold-vibration
Description: Distraction method
Study NCT02971202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyperinsulinemic, euglycemic clamp
Description: Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
Study NCT02971202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 20% dextrose
Description: A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.